...
首页> 外文期刊>The Lancet >Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial.
【24h】

Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial.

机译:ST段抬高型心肌梗死患者的自体骨髓源性干细胞转移:双盲,随机对照试验。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: The benefit of reperfusion therapies for ST-elevation acute myocardial infarction (STEMI) is limited by post-infarction left-ventricular (LV) dysfunction. Our aim was to investigate the effect of autologous bone marrow-derived stem cell (BMSC) transfer in the infarct-related artery on LV function and structure. METHODS: We did a randomised, double-blind, placebo-controlled study in 67 patients from whom we harvested bone marrow 1 day after successful percutaneous coronary intervention for STEMI. We assigned patients optimum medical treatment and infusion of placebo (n=34) or BMSC (n=33). Our primary endpoint was the increase in LV ejection fraction and our secondary endpoints were change in infarct size and regional LV function at 4 months' follow-up, all assessed by MRI. We assessed changes in myocardial perfusion and oxidative metabolism with serial 1-[11C]acetate PET. Analyses were per protocol. This study is registered with , number NCT00264316. FINDINGS: Mean global LV ejection fraction 4 days after percutaneous coronary intervention was 46.9% (SD 8.2) in controls and 48.5% (7.2) in BMSC patients, and increased after 4 months to 49.1% (10.7) and 51.8% (8.8; OR for treatment effect 1.036, 95% CI 0.961-1.118, p=0.36). Compared with placebo infusion, BMSC transfer was associated with a significant reduction in myocardial infarct size (BMSC treatment effect 28%, p=0.036) and a better recovery of regional systolic function. Myocardial perfusion and metabolism increased similarly in both groups. We noted no complications associated with BMSC transfer and all but one patient in the BMSC group completed the 4 months' follow-up. INTERPRETATION: Intracoronary transfer of autologous bone marrow cells within 24 h of optimum reperfusion therapy does not augment recovery of global LV function after myocardial infarction, but could favourably affect infarct remodelling.
机译:背景:再灌注疗法对ST抬高急性心肌梗死(STEMI)的益处受到梗死后左心室(LV)功能障碍的限制。我们的目的是研究梗死相关动脉中自体骨髓干细胞(BMSC)转移对左室功能和结构的影响。方法:我们对67例患者进行了一项随机,双盲,安慰剂对照研究,这些患者在成功经皮冠状动脉介入治疗STEMI后1天获得了骨髓。我们为患者分配了最佳的药物治疗和安慰剂(n = 34)或BMSC(n = 33)输注。我们的主要终点是左室射血分数的增加,而我们的次要终点是在随访4个月时梗死面积和局部左室功能的改变,所有这些均通过MRI评估。我们用1- [11C]醋酸酯PET评估了心肌灌注和氧化代谢的变化。根据方案进行分析。该研究已注册,编号为NCT00264316。结果:经皮冠状动脉介入治疗后4天,对照组的平均总左室射血分数为46.9%(SD 8.2),而BMSC患者为48.5%(7.2),并在4个月后增加至49.1%(10.7)和51.8%(8.8; OR治疗效果1.036,95%CI 0.961-1.118,p = 0.36)。与安慰剂输注相比,BMSC转移与心肌梗塞面积的显着减少有关(BMSC治疗效果为28%,p = 0.036),并且区域收缩功能恢复更好。两组的心肌灌注和代谢相似地增加。我们注意到没有与BMSC转移相关的并发症,BMSC组中只有一名患者完成了4个月的随访。解释:最佳再灌注治疗后24小时内,自体骨髓细胞的冠状动脉内转移不会增加心肌梗死后整体LV功能的恢复,但可能会有利地影响梗塞重塑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号